Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Anika Therapeutics (ANIK) over the last 13 years, with Sep 2025 value amounting to -$13,000.

  • Anika Therapeutics' Cash from Financing Activities rose 99.67% to -$13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.6 million, marking a year-over-year decrease of 51.09%. This contributed to the annual value of -$12.7 million for FY2024, which is 101.28% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Cash from Financing Activities is -$13,000, which was down 107.26% from $179,000 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Cash from Financing Activities ranged from a high of $667,000 in Q4 2022 and a low of -$7.0 million during Q3 2021.
  • In the last 3 years, Anika Therapeutics' Cash from Financing Activities had a median value of -$1.6 million in 2023 and averaged -$2.2 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 1,011.67% in 2022, then plummeted by 10,645.65% in 2023.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Cash from Financing Activities stood at $60,000 in 2021, then skyrocketed by 1,011.67% to $667,000 in 2022, then crashed by 48.73% to $342,000 in 2023, then slumped by 1,665.50% to -$5.4 million in 2024, then skyrocketed by 99.67% to -$13,000 in 2025.
  • Its last three reported values are -$13,000 in Q3 2025, $179,000 for Q2 2025, and -$5.4 million during Q1 2025.